top of page


  1. Lee N, Fawaaz R, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 531 patients. Int J Radial Oncol Phys 2000, 48:1443.

  2. Cimadamore, A., Cheng, M., Santoni, M., Lopez-Beltran, A., Batteli, N., Massari, F., B. Galosi, A., Scarpelli, M., Montironi, R. New Prostate Cancer Targets for Diagnosis, Imaging and Theraphy: Focus on Prostate-Specific Membrane Antigen. Genitourinary Oncology, journal Frontiers in Oncology, 2018; 8:653.

  3. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 2001; 45:53.

  4. Yang HL, Liu, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21:20164.

  5. Giovacchini, G., Guglielmo, P., Mapelli, P., Incerti, E., Samanes, A.M., Giovannini, E, Riondato, M. 11-C-choline PET/CT predicts survival in prostate cáncer patients with PSA < 1 ng/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2018; 1-9.

  6. Huang, S., Yin, L., Yue, J., Li, Y., Lin, Z. Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer. Systematic review and Metha-Analysis. Medicine 2018; 97:50 (e1344).

  7. Ozyigit G., Hurmuz P., Yuce Sari S., Onal C., Biltekin F., Gultekin M., Yazici G., Cem Guler O., and Fadil Akyol. Gentourinary System Cancers. In: Ozyigit, Gokhan, Selek, Ugur, editors. Radiation Oncology - A case-based review. Berlin: Springer. Department of Radiation Oncology. University of Texas of MD Anderson. 2018. p. 280-296.

  8. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol. 2006;79(3):259–69.

  9. Buyyounouski MK, He P, Jr RA, Feigenberg SJ, Pollack A, Prostate IMRT. In: Bortfeld TS-UR, De Neve W, Wazer DE, editors. Image-guided IMRT.  Berlin: Springer; 2006. p. 391–410.

  10. Desai NZM. Prostate Adenocarcinoma. In: Lee NY, et al., editors. Target volume delineation and field setup, a practical guide for conformal and intensity-modulated radiation therapy. Berlin: Springer; 2013. p. 213–226.

  11. Ozyigit G., Hurmuz P., Yuce Sari S., Onal C., Biltekin F., Gultekin M., Yazici G., Cem Guler O., and Fadil Akyol. Gentourinary System Cancers. In: Ozyigit, Gokhan, Selek, Ugur, editors. Radiation Oncology - A case-based review. Berlin: Springer. Department of Radiation Oncology. University of Texas of MD Anderson. 2018. p. 284-285; 287-296.

  12. Long-term results of intensity-modulated radiotheraphy with three dose-fractionation regimens for localized prostate cancer. Takemoto, S., Shibamoto, Y., Sugie, C, Manabe, Y., Iwata, H., Murai, T., Ishikura, S. Journal Radiation Research, 2018; 1093, 89.

  13. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer. ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; JCO 1800606.

  14. National Comprehensive Cancer Network. Prostate Cancer (Version 1.2018). Accessed December 29, 2018.

  15. Takemoto, S., Shibamoto, Y., Sugie, C, Manabe, Y., Iwata, H., Murai, T., Ishikura, S. Long-term results of intensity-modulated radiotheraphy with three dose-fractionation regimens for localized prostate cancer. Journal Radiation Research, 2018; 1093, 89.

  16. Dibiase SJ, Roach M, Lizaraga TL, Lazar AA. External beam radiation theraphy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 2018; 93: 1064.

  17. Melian E, Mageras GS, Fuks Z, et al. Variation in prostate position quantitation and implications for three-dimensional conformal treatment plannning. Int J Radiat Oncol Biol Phys 1997 – 2018; 38:73.

  18. Chen RC, Basak R, Meyer AM, et al. Association Between Choice of Radical Prostatectomy, External Beam Radiotheraphy, Brachytheraphy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA 2017; 317:1141.

  19. López Torrecilla J, Grupo URONC-OR. Cáncer de Próstata: Enfoque multidisciplinar. Madrid: Medical Practice Group; 2007.

  20. Guinot JL, Lanzós E, Muñoz V, Polo A, Ramos A. Guía de Braquiterapia. Madrid: Medical Practice Group; 2008.

  21. Ash D, Flynn A, Battermann J, de Reijke T, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57(3):315-21.

  22. Davis BJ, Horwitz EM, Lee WR, Crook JM, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. 2012, Brachytherapy. 2012;11(1):6-19.

  23. Hoskin PJ, Colombo A, Henry A, Niehoff P, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol.. 2013 Jun;107(3):325-32.

  24. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2019.

  25. Prada PJ, Ferri M, Cardenal J, Blanco AG, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results. Brachytherapy. 2018;17(6):845-851.

  26. Prada PJ, Jimenez I, González-Suárez H, Fernández J, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy. 2012;11(2):105-10.

  27. International Commission on Radiation Units and Measurement (ICRU). Dose and volume specification for reporting interstitial therapy. Report No 58 of ICRU. ICRU Publications, Bethesda (MD); 1997.

  28. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P, Tunn UW.: Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.Int J Clin Pract. 2004 Apr;58(4):382-90.

  29. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.Urology. 1994 May;43(5):649-59.

  30. Han M1, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancerJ Urol. 2003 Feb;169(2):517-23..

  31. Lindenberg ML, Turkbey B, Mena E, Choyke PL.: Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.JAMA  Oncol. 2017 Oct 1;3(10):1415-1422. doi: 10.1001/jamaoncol.2016.5840.

  32. ScherHI,Eisemberger M, D’Amico AV, et al: Eligibility and aoutcomes reporting guidelines for clinical trials for patients in the state of a rising prostate specific antigen:  recommendations from prostate Specific Antigen Working Group . J Clin Oncol  2004 22(3) 537-56.

  33. Saleem MD, Sanders H, Elnase MA, et al_ Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998 51:283-6.

  34. Sandgren K, Westerlinck P, Jonsson JH, et al. Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy—a systematic review. Eur Urol Focus 2017; published online Nov 11. DOI:10.1016/j.euf.2017.11.001

  35. Evangelista L, Zattoni F, Rossi E, Karnes J Lowe V. Earlyt detection of prostate cancer relapse by biochemistry and diagnostic imaging.  J Nucl Med Mol Imaging 59 359-73, 2015.

  36. Rischke HC, SchaferAO, Nestle U, VolegovaN, Henne K, Benz M: Detection of local recurrent prostate cancer after radical prostatectomy in terms of a salvage radiotherapy using dynamic contrast enhanced MRI without endorectal coil. Radiat Oncol. 7: 185. 2012.

  37. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 1⁸F-fluoromethyl choline versus ⁶⁸Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185–90

  38. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a ⁶⁸Ga-labelled PSMA ligand and 1⁸F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11–20.

  39. NCCN prostate guidelines V 4,2018,

  40. Ploussard  G, Gandaglia G,  Borgmann H, de Visschere P, Heidegger I, Kretschmer A, Mathieu R, Surcel ,  Tilki , Tsaur I, Valerio M, van den Bergh R, Ost P, Briganti A:Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. Eur Urol (2018), .

  41. Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy—what is the best time to treat? Radiother Oncol 2012;103:239–43.

  42. Kwon O, Kim KB, Lee YI, et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014;9:e103574.

  43. Fossati N,Karnes RJ,Boorjian SA, et al: Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate CancerPatients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.Eur Urol. 2017 Jun;71(6):886-893. doi: 10.1016/j.eururo.2016.07.028. Epub 2016 Jul 30.

  44. Giorgio Gandaglia , Alberto Briganti , Noel Clarke, R. Jeffrey Karnes, Markus Graefen,Piet Ost , Anthony Laurence Zietman , Mack Roach III: Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients Eur Urol.  ( 2 0 1 7 ) 6 8 9 – 7 0 9.

  45. Identifier: NCT00567580

  46. Ghadjar P, Hayoz S, Bernhard J, et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically.recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 2015;33:4158–66.

  47. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol 2016;17:747–56.

  48. Shipley WU, Pugh SL, Lukka HR, et al. NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. J Clin Oncol 2016;34(Suppl 2S):abstr 3.

  49. Gonzalez-San Segundo C, et al. Androgen Deprivation Therapy and Salvage Radiotherapy: Are We Missing Something? Eur Urol (2019),

  50. Abdollah F,Dalela D,Sood A, Keeley J, Alanee S,Briganti A,Montorsi F,Peabody JO, Menon M2.Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.Eur Urol. 2018 Sep;74(3):253-256. doi: 10.1016/j.eur uro.2018.04.017. Epub 2018 Apr 30

  51. Malone S, Croke J, Roustan-Delatour N, Belanger E, Avruch L, Malone C, et al. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomother-apy IMRT. Int J Radiat Oncol Biol Phys (2012) 84(3):725–32. doi:10.1016/j. ijrobp.2011.12.081.

  52. Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Therapy Oncology Group. Radiotherapy Oncol 2007;84:121e127.

  53. Andriole GL, Kostakoglu L , Chau A, Duan F ,Mahmood U, Mankoff  DA, Schuster DM , Siegel BA: The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial  J Urol. 2019 Feb;201(2):322-331. doi: 10.1016/j.juro.2018.08.050.

  54. Jani, A. B., Schreibmann, E., Rossi, P. J. et al.: Impact of 18F-fluciclovine PET on target volume definition for postprostatectomy salvage radiotherapy: initial findings from a randomized trial. J Nucl Med, 58: 412, 2017.

  55. Gonzalez‑San Segundo C, Jové J,  Zapatero A, Pastor‑Peidro J, Vázquez ML, Casaña  M, Mengual JL, Gomez‑Caamano A , Gomez‑Iturriaga A, Vallejo C, Henríquez I, Munoz‑Garcia JL, Clemente J, Porras M,  Collado M, Ossola  G, Villafranca  E, Cabeza  MA, Lopez‑Torrecilla  J: Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes Clin Transl Oncol. 2019 Jan 7. doi: 10.1007/s12094-018-02021-7.

  56. Pazona J,  Han M*,  Hawkins  SH,  Roehl KA, Catalona WJ: Salvage Radiation therapy for prostate antigen specific progression following radical prostatectomy: 10 year outcome estimates. J Urol 2005 Vol. 174, 1282–1286.

  57. Fizazi K et al. Patient-reported outcomes following abiraterone acetat plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastasic castration-naive prostate cáncer (LATITUDE): an international. randomised phase 3 trial. N Engl J Med. 2017;377(4):352-60.

  58. James, ND et al. Abiraterona for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:388-51.

  59. Sweeney CJ et al. Ann Oncol 2016;27(suppl 6). Chemohormonal Theraphy in Metastasic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805. CHAARTED Trial. N Engl J Med. 2015; 373:737-46.

  60. James, ND et al. Survival with Newly Diagnosed Metastasic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PRO8, CRUK/06/019). Lancet. 2016; 387:1163-77.

  61. Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 2017; 35:3189.

  62. Miller K, et al. The phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason score. Eur. Urol. 2018. Jul;74(1):17-23.

  63. Fizazi K et al. The phase 3 COU-AA-301 Study of Abiraterone Acetate Plus Prednisone in Men after Chemotherapy in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jul;74(1):17-23.

  64. Evans C, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Oct;70(4):675-683.

  65. Scher et al. Increased survival with enzalutamide in prostate cancer after chemotherapy (AFFIRM). N Engl J Med 2012; 367:1187-1197.

  66. Hussain M et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). N Engl J Med. JCO.2018.36.6_suppl.3

  67. Smith MR et al. SPARTAN Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.  N Engl J Med 2018; 378:1408-1418.

  68. Parker C, et al. ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer). N Engl J Med. 2013;369(3):213-23. 

  69. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004;58:3–10.

  70. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2017; 73: 178–211.

  71. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378–82.

  72. Schweizer MT, Zhou XC, Wang H, et al. Metastasis-free survival is

  73. associated with overall survival in men with PSA-recurrent pros- tate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013;24:2881–6.

  74. Ost P, Decaestecker K, Lambert B, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014;74:297–305.

  75. Ost P., Bossi A., Decaestecker K., et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. European Urology 2015;67(5):852-863.

  76. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometa- static prostate cancer. Front Oncol 2013;2:215.

  77. Habl G, Straube C, Schiller K, et al. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 2017;17:361.

  78. Niibe Y, Chang JY. Novel insights of oligometastases and oligo- recurrence and review of the literature. Pulm Med 2012;2012:261096.

  79. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353–7.

  80. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis­directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36: 446–53.

  81. Battaglia A, et al. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. Eur Urol Oncol (2018)(in press)

  82. Conde Moreno, A., Lopez Campos, F., Hervás Morón, A., Vallejo Ocaña, C., Valero Albarrán, J., Mendez Villamón, A., et al. OC-0062: Phase II trial of SBRT and hormone therapy for oligometastases in prostate cancer (SBRT-SG 05). Radiotherapy and Oncology, 127, S27–S28.

  83. US National Library of Medicine.

  84. US National Library of Medicine. ClinicalTrials.gov

  85. US National Library of Medicine. ClinicalTrials.gov

  86. US National Library of Medicine.

  87. US National Library of Medicine.

  88. US National Library of Medicine. ClinicalTrials.gov (2016).

  89. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer. 2017 Jun 29;17(1):453.

  90. US National Library of Medicine. ClinicalTrials.gov (2016).

  91. US National Library of Medicine. ClinicalTrials.gov (2016).

  92. Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer. 2015 Sep 25;15:646

  93. Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.

  94. Moyer VA; US Preventive Services Task Force. Screening for bladder cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155:246-251.

  95. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case‐control smoking studies. Int J Cancer 2000 Apr 15;86(2):289‐94.

  96. Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, et al. Influence of smoking status on the disease‐related outcomes of patients with tobacco‐associated superficial transitional cell carcinoma of the bladder. Cancer 1999 Dec 1;86(11):2337-45.

  97. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl 4):S193–8.

  98. Messing EM, and Vaillancourt A: Hematuria screening for bladder cancer. J Occup Med 32: 838-845, 1990.

  99. Bastacky S, Ibrahim S, Wilczynski SP, et al: The accuracy of urinary cytology in daily practice. Cancer 87: 118 –128, 1999.

  100. Silmi Moyano.A., Moreno Sierra.J., Blázquez Izquierdo.J., Fuentes Marquez.I. Diagnóstico endoscópico de las neoplasias de vejiga. In: Resel Estévez, L., Moreno Sierra, J. Tratado de oncología urológica. Tomo I. ASTRAZANECA Ed. 2003:159-162

  101. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846-854.

  102. Fernández González I, Moreno Santurino A, Llanes González L, Berenguer Sánchez A. Métodos diagnósticos en el cáncer vesical. In: Resel Estévez, L., Moreno Sierra, J. Tratado de oncología urológica. Tomo I. ASTRAZANECA Ed. 2003:505-514

  103. Shinagare AB, Ramaiya RH, Jagannathan JP, et al. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol 2011;196:117-122.

  104. Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 2014;114:389-395.

  105. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-465

  106. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical
trials. J Urol 2004;171:2186-2190

  107. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin
reduce recurrence in patients with superficial bladder cancer? A meta- analysis of randomized trials. Urology 2006;67:1216-1223

  108. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin:
a prospective, randomized clinical trial. J Urol 2006;175:1641-1644.

  109. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin
reduce recurrence in patients with superficial bladder cancer? A meta- analysis of randomized trials. Urology 2006;67:1216-1223.

  110. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24:296–304.

  111. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008;112:2401- 2408

  112. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Can- cer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemother- apy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–7. 

  113. González del Alba, A., De Velasco, G., Lainez, N., et al. SEOM clinical guideline for treatment of muscle‐invasive and metastatic urothelial bladder cancer (2018). Clin Transl Oncol. (2019) 21:64–74.

  114. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.

  115. Zaghloul MS, Christodouleas JP, Smith A, et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone
for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. JAMA Surg 2017:e174591

  116. Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017; 71:952-960.

  117. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.

  118. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; 32:3801-09.

  119. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-88.

  120. Huddart RA, Hall E, Lewis R, et al. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int 2010; 106:753-55.

  121. Vashistha V, Wang H, Mazzone A, et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017; 97(5): 1002–1020.

  122. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012; 61:705-711.

  123. Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conven- tional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):197-207. 

  124. Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139-44. 

bottom of page